|
|
|
front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |review |
 |
Diagnostic criteria from ATP III, WHO and IDF vary enough that
different segments of
populations are identified as having MS .
Emphasizes the need to treat individually all components of the
syndrome.
It is still important to
recognize that clustering of CVD risk factor does occur and to be astute
in
looking for and addressing all the factors.
As more research is done
the underlying common biochemical denominators are being identified
and medications are being developed that address the root causes of the
various components of the syndrome
|